 NEW YORK, Dec. 02, 2022 GLOBE NEWSWIRE -- Ovid Therapeutics Inc. NASDAQ: OVID, a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society AES Annual Meeting, taking place December 2-6 in Nashville, Tennessee. 